The reduction in price target by HC Wainwright & Co. could have a mixed impact on Relay Therapeutics' stock price. While the lowered target may suggest a more conservative valuation, the maintenance of a Buy rating indicates continued confidence in the company's prospects. This could lead to a neutral short-term impact as the market digests both the positive and negative aspects of the analyst's updated stance.